Cisapride In Treatment Research Articles

Elenoside increases intestinal motility

To study the effects of elenoside, an arylnaph-thalene lignan from Justicia hyssopifolia, on gastro-intestinal motility in vivo and in vitro in rats. Routine in vivo experimental assessments were catharsis index, water percentage of boluses, intestinal transit, and codeine antagonism. The groups included were vehicle control (propylene glycol-ethanol-plant oil-tween 80), elenoside (i.p. 25 and 50 mg/kg), cisapride (i.p. 10 mg/kg), and codeine phosphate (intragastric route, 50 mg/kg). In vitro approaches used isolated rat intestinal tissues (duodenum, jejunum, and ileum). The effects of elenoside at concentrations of 3.2 x 10(-4), 6.4 x 10(-4) and 1.2 x 10(-3) mol/L, and cisapride at 10(-6) mol/L were investigated. Elenoside in vivo produced an increase in the catharsis index and water percentage of boluses and in the percentage of distance traveled by a suspension of activated charcoal. Codeine phosphate antagonized the effect of 25 mg/kg of elenoside. In vitro, elenoside in duodenum, jejunum and ileum produced an initial decrease in the contraction force followed by an increase. Elenoside resulted in decreased intestinal frequency in duodenum, jejunum, and ileum. The in vitro and in vivo effects of elenoside were similar to those produced by cisapride. Elenoside is a lignan with an action similar to that of purgative and prokinetics drugs. Elenoside, could be an alternative to cisapride in treatment of gastrointestinal diseases as well as a preventive therapy for the undesirable gastrointestinal effects produced by opioids used for mild to moderate pain.

Cisapride for treatment of non-ulcer dyspepsia (NUD): A meta-analysis of randomized controlled trials

Cisapride for treatment of non-ulcer dyspepsia (NUD): A meta-analysis of randomized controlled trials

A comparison between Zhishi Xiaopiwan and cisapride in treatment of functional dyspepsia.

AIM:To compare the therapeutic effect of the herbal medicine Zhishi Xiaopi with that of Cisapride in the treatment of functional dyspepsia (FD).METHODS:Fifty-one FD patients were randomized into Herbal group (n =27) and Cisapride group (n =24). Two two groups were given a four-week treatment of Zhishi Xiaopi 100ml, tid, a.c. and Cisapride 5mg, tid, a.c. respectively. Patients' symptoms were assessed and 39 patients'(22 of Herbal group and 17 of Cisapride group) gastric liquid emptying times were measured with ultrasonography before and after the treatment.RESULTS:The therapeutic effective rates of Herbal group and Cisapride group were 81.49% and 87.50% (P> 0.05). The half gastric emptying time (GET50) and gastric emptying time (GET) of healthy controls and FD patients were 36.12min ± 10.22min vs 52.95min ± 13.49min and 87.07min ± 21.11min vs 120.74min ± 23.08min (P < 0.001).The GET(50) and GET of Herbal group before and after the treatment were 51.63min ± 13.15min vs 45.62min ± 10.82min and 117.34min ± 23.29min vs 103.26min ± 22.19min (P < 0.01). The results of Cisapride group were 54.66min ± 14.14min vs 40.95min ± 11.29min and 125.12min ± 24.47minvs 95.49min ± 22.31min (P < 0.01). The differences in values (median) of GET(50) and GET for Herbal group and Cisapride group before and after treatment were 5.75min vs 17.18min and 13.22min vs 33.54min (P < 0.05). CONCLUSION:Delayed gastric emptying is one of the pathogenesis of FD. Both Zhishi Xiaopi pills and Cisapride can effectively alleviate the symptoms of FD and accelerate gastric liquid emptying.The effect of Zhishi Xiaopiwan on enhancing gastric motility is comparable with but less than that of Cisapride.

Author's Reply: Use of Cisapride in Treatment of Idiopathic Constipation in Children

Author's Reply: Use of Cisapride in Treatment of Idiopathic Constipation in Children

Controled clinical trial on cisapride in treatment of chronic cholecystitis

Controled clinical trial on cisapride in treatment of chronic cholecystitis

Anti-reflux therapy — why, when and how

During the last 10 years there has been a resurgence of interest in gastroesophageal reflux (GOR). Fresh impetus has been provided by firstly the development of new and better methodologies for evaluating GOR and secondly by the availability of newer and better pharmacological agents such as cisapride for treatment. Development and availability of oesophageal pH monitoring, a more accurate method of diagnosis than barium mealle3 have enabled identification of a number of symptoms not previously known to be caused by reflux, particularly silent reflux.4 Our understanding of the pathophysiology has increased, but the condition has nevertheless become more complex to evaluate and treat. The purpose of this paper is to transform this new understanding into rational therapy for GOR. The definition of GOR is, the involuntary passage of gastric contents into the oesophagus. It does not specify any specific aetiology and may be primary or secondary.

Cisapride in treatment of roux-en-Y syndrome

After Roux-en-Y gastrojejunostomy patients frequently complain of upper abdominal pain, fullness, nausea, and vomiting. This Roux-en-Y syndrome is caused by slow gastric emptying, Roux-limb stasis, or both. Treatment of this syndrome is cumbersome. We evaluated the effect of cisapride on complaints and on transit through gastric remnant and Roux limb in 24 such patients. Thirteen of them had slow gastric emptying and 13 had stasis in the Roux limb (two patients had both). Symptoms and transit were evaluated before and after three weeks of treatment using a questionnaire and scintigraphy. Responding subjects continued therapy and were interviewed again after six months. Seven patients with slow gastric emptying and three patients with Roux-limb stasis had enduring symptomatic relief; all exhibited accelerated transit during therapy: mean half gastric emptying time in the seven patients with slow gastric emptying was 204 +/- 89 min before and 111 +/- 59 min during cisapride (P less than 0.05); mean percentage of radioactivity, emptied from the gastric remnant, which remained in the Roux limb at 60 min in the three patients with Roux limb stasis was 74 +/- 4% before and 25 +/- 10% during cisapride (P less than 0.05). In patients without symptomatic response, transit did not improve. with cisapride long-lasting symptomatic relief and improved transit is achieved in about 40% of patients with the Roux-en-Y syndrome.